Skip to main content
All lobbying filings

PRIME THERAPEUTICS

Lobbying for PRIME THERAPEUTICS

 Filing 3rd Quarter - Report
3rd Quarter (July 1 - Sep 30) 2025 · Minnesota · House · Senate · $100,000.00 expenses · posted Oct 16, 2025

Official filing document

 Bills named in this filing 7
  • S 891
    Bipartisan Health Care Act
  • HR 2214
    DRUG Act
  • S 526
    Pharmacy Benefit Manager Transparency Act of 2025
  • HR 4231
    Treat and Reduce Obesity Act of 2025
  • HR 4317
    PBM Reform Act of 2025
  • HR 10445
    Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
  • HR 5378
    Lower Costs, More Transparency Act
 Lobbying activity 3
Health Issues

S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation Draft legislation, Patients Before Middlemen regarding payor ownership of pharmacies General education on ERISA and PBMs

Medicare/Medicaid

S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4231 Treat and Reduce Obesity Act-provisions related to coverage of obesity medications in Medicare H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards

Trade (domestic/foreign)

Tariffs on pharmaceuticals.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem